ONK Therapeutics names new CSO

Ireland and USA-based natural killer (NK) cell therapy biotech ONK Therapeutics has named Bruce McCreedy as chief scientific officer (CSO). As a member of the company’s executive leadership team, he will be based in the USA.

Dr McCreedy succeeds ONK’s former CSO and scientific founder Professor Michael O’Dwyer, who is making a planned return to the role of full-time Professor of Hematology, but he remains as a board director of the company and as a scientific advisor providing ongoing expert counsel as ONK continues to grow and progress.

Renowned as an immunologist and cell and gene therapy expert, Dr McCreddy brings over three decades of experience in drug development, including differentiated gene-edited, cell therapy products. He has been responsible for leading research organizations through the design and execution of highly successful drug development programs including currently marketed products.